These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 24393856)

  • 1. [Treatment outcome of peptide vaccination for advanced colorectal cancer].
    Sugiura F; Inoue K; Kogita A; Yoshioka Y; Hida J; Okuno K; Sukegawa Y
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1584-6. PubMed ID: 24393856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study of Peptide-cocktail vaccination with tegafur-uracil/leucovorin for advanced colorectal cancer].
    Sugiura F; Inoue K; Okuno K; Sukegawa Y
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):1760-2. PubMed ID: 23267878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer].
    Inoue K; Sugiura F; Kogita A; Yoshioka Y; Sukegawa Y; Hida J; Okuno K
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1276-9. PubMed ID: 25335716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preliminary study of Peptide vaccine with UFT/LV as adjuvant setting for stage III colorectal cancer].
    Okuno K; Sugiura F; Hida J; Tokoro T; Ishimaru E; Ueda K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1906-8. PubMed ID: 22202234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
    Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
    Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
    Kanekiyo S; Hazama S; Takenouchi H; Nakajima M; Shindo Y; Matsui H; Tokumitsu Y; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Okuno K; Udaka K; Kawakami Y; Matsueda S; Ito K; Nagano H
    Oncol Rep; 2018 May; 39(5):2385-2392. PubMed ID: 29498403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
    Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
    J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer.
    Okuno K; Sugiura F; Inoue K; Sukegawa Y
    Anticancer Res; 2014 Jun; 34(6):3045-52. PubMed ID: 24922671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
    Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
    Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
    Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
    Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.
    Kawamura J; Sugiura F; Sukegawa Y; Yoshioka Y; Hida JI; Hazama S; Okuno K
    Cancer Sci; 2018 May; 109(5):1545-1551. PubMed ID: 29473265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer.
    Hsiao SC; Lin JF; Chuang MT; Lee YA; Wu DL
    Int Surg; 2009; 94(4):298-303. PubMed ID: 20302025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Nagase H; Uchida J
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):285-91. PubMed ID: 22752215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.
    Hochster HS; Luo W; Popa EC; Lyman BT; Mulcahy M; Beatty PA; Benson AB
    J Clin Oncol; 2007 Dec; 25(34):5397-402. PubMed ID: 18048821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
    J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
    Hattori T; Mine T; Komatsu N; Yamada A; Itoh K; Shiozaki H; Okuno K
    Cancer Immunol Immunother; 2009 Nov; 58(11):1843-52. PubMed ID: 19396597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients].
    Mizushima T; Mizuno H; Ito T; Hoki M; Souma Y; Iwamoto T; Ozawa H; Kanou T; Nakamori Y; Iwase K
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):941-4. PubMed ID: 16835484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in γ-glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Kamijo A; Nagase H; Uchida J
    Anticancer Res; 2013 Aug; 33(8):3431-8. PubMed ID: 23898115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer.
    Shibahara K; Yamamoto M; Kakeji Y; Sakata H; Maehara Y
    Anticancer Res; 2008; 28(3B):1779-83. PubMed ID: 18630459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
    Bin Q; Li J; Liao C; Cao Y; Gao F
    Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.